Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerNeoplasia: the second decade.Biocompatibility and reduced drug absorption of sol-gel-treated poly(dimethyl siloxane) for microfluidic cell culture applications.Preclinical models for neuroblastoma: establishing a baseline for treatmentMyc proteins as therapeutic targets.miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAsGalectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cellsmiR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.Glial progenitors as targets for transformation in glioma.Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastomaExosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy.Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.Targeting ALK in neuroblastoma--preclinical and clinical advancements.Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.Neuroblastoma and MYCNMdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivoThe War on Cancer rages on.Apoptotic cell death in neuroblastoma.p53 family: Therapeutic targets in neuroblastoma.Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.Neuroblastoma models for insights into tumorigenesis and new therapies.Targeting p53-null neuroblastomas through RLIP76.p53 is a direct transcriptional target of MYCN in neuroblastomaOncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.Influence of p53 expression on sensitivity of cancer cells to bleomycin.Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.miR-10a rejuvenates aged human mesenchymal stem cells and improves heart function after myocardial infarction through KLF4.
P2860
Q24628746-49F17A89-17E7-4D5A-95BA-D78B68DD1E1DQ30484000-9DF5C678-B292-412C-B559-B921884BBB58Q30498060-6708774C-EDAA-4389-8494-889ABBDA83ADQ33895108-514B6420-A16E-4C5F-A23B-D007879BB745Q33997741-3501A3B5-CD17-487C-B96B-5AE714CF85A7Q34099211-EAD97E98-55D0-459F-B1D8-E78BBD104C61Q34477775-E7240F86-0EEA-4906-82E6-748B92DC2A1DQ34482630-7E69F168-1D2E-4B30-BA53-E94C60311594Q34531771-93B661C5-96A9-4923-B97C-90CD9193A1D7Q34735661-7186ED14-70B1-4A73-A2DC-5BFC7883B46FQ34983575-FC63040D-31B3-4F80-8B57-678F98233047Q36691028-BC58FF8D-DD9B-4F8A-A5EF-8A576EA0590AQ36890860-0B96B016-AF82-4450-866A-DF9CE2330945Q36933081-1A315AD1-25B1-42C9-962E-918F93219777Q37163339-8A6FEB40-D1EC-42A0-8202-E4F8CDF575FAQ37201479-2F77FE34-1EB0-4BA6-A4BC-32C10381A95BQ37268813-908B1E99-D554-46B8-93A7-A7B5BF95937DQ37478602-485BFE58-3D43-49A6-9DAF-467E0CDA3E1AQ37679253-25F40AD4-F28B-4453-810C-5B4FF23B81E9Q37707387-009EFEF1-964A-478D-B177-064FA02A40BCQ37826751-0B192661-EDB3-4D85-B9CE-218D0A0FF5F8Q37940719-B95AD069-C4EA-4EED-8474-49CD52D77959Q38262762-80A30314-222A-4C28-9960-5A9DD758E151Q38336615-CC10025B-7A4F-4654-926C-C94B550C7BD6Q38346566-96EE1CF4-A009-4F4C-B701-8777325180D4Q39188198-9C0775D3-8E89-429B-96E7-3A3B042E0887Q39225715-4A526D8F-FF38-45F2-B131-32DB15E61B5AQ39294214-C5D559D6-EBBC-4FAC-9764-64092316D9B7Q39392756-59296E6B-144E-4B3F-969F-621C85CAF598Q39743164-0DACDB78-D33A-4C6A-8602-81B5F68A1084Q40596524-76965730-54EB-4B0D-B059-C0928E9E1029Q42362115-4633A6A1-859D-4498-A879-6E021592FEC1Q43297978-11BFB847-0D78-4081-977B-79967403BE0EQ55396217-2C77EF3F-9EFD-4926-8171-4E574214DAAB
P2860
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Chemotherapy-induced apoptosis ...... roceeds through p53 induction.
@en
type
label
Chemotherapy-induced apoptosis ...... roceeds through p53 induction.
@en
prefLabel
Chemotherapy-induced apoptosis ...... roceeds through p53 induction.
@en
P2093
P2860
P356
P1433
P1476
Chemotherapy-induced apoptosis ...... roceeds through p53 induction.
@en
P2093
David D Goldenberg
Grace E Kim
Katherine K Matthay
Kim Nguyen
Louis Chesler
Matt Grimmer
Rodney Collins
Slava Yakovenko
Tarik Tihan
William A Weiss
P2860
P304
P356
10.1593/NEO.08778
P577
2008-11-01T00:00:00Z